Logo image of AQST

AQUESTIVE THERAPEUTICS INC (AQST) Stock Fundamental Analysis

NASDAQ:AQST - Nasdaq - US03843E1047 - Common Stock - Currency: USD

3.25  -0.15 (-4.41%)

After market: 3.1801 -0.07 (-2.15%)

Fundamental Rating

2

AQST gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. AQST may be in some trouble as it scores bad on both profitability and health. AQST is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AQST had negative earnings in the past year.
AQST had a negative operating cash flow in the past year.
In the past 5 years AQST always reported negative net income.
AQST had a negative operating cash flow in each of the past 5 years.
AQST Yearly Net Income VS EBIT VS OCF VS FCFAQST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -53.05%, AQST is doing worse than 62.05% of the companies in the same industry.
Industry RankSector Rank
ROA -53.05%
ROE N/A
ROIC N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQST Yearly ROA, ROE, ROICAQST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

AQST has a better Gross Margin (68.40%) than 75.90% of its industry peers.
AQST's Gross Margin has improved in the last couple of years.
AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
AQST Yearly Profit, Operating, Gross MarginsAQST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AQST has been increased compared to 1 year ago.
AQST has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AQST has an improved debt to assets ratio.
AQST Yearly Shares OutstandingAQST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AQST Yearly Total Debt VS Total AssetsAQST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

AQST has an Altman-Z score of -4.01. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
AQST's Altman-Z score of -4.01 is in line compared to the rest of the industry. AQST outperforms 41.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.01
ROIC/WACCN/A
WACC10.96%
AQST Yearly LT Debt VS Equity VS FCFAQST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

AQST has a Current Ratio of 4.87. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
AQST has a better Current ratio (4.87) than 70.26% of its industry peers.
A Quick Ratio of 4.48 indicates that AQST has no problem at all paying its short term obligations.
AQST has a better Quick ratio (4.48) than 68.21% of its industry peers.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 4.48
AQST Yearly Current Assets VS Current LiabilitesAQST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AQST have decreased strongly by -43.90% in the last year.
AQST shows a small growth in Revenue. In the last year, the Revenue has grown by 5.30%.
AQST shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.82% yearly.
EPS 1Y (TTM)-43.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.18%
Revenue 1Y (TTM)5.3%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-27.65%

3.2 Future

Based on estimates for the next years, AQST will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.83% on average per year.
The Revenue is expected to grow by 31.32% on average over the next years. This is a very strong growth
EPS Next Y-36.33%
EPS Next 2Y-10.81%
EPS Next 3Y11.48%
EPS Next 5Y19.83%
Revenue Next Year-23.28%
Revenue Next 2Y4.41%
Revenue Next 3Y18.57%
Revenue Next 5Y31.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AQST Yearly Revenue VS EstimatesAQST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AQST Yearly EPS VS EstimatesAQST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AQST. In the last year negative earnings were reported.
Also next year AQST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQST Price Earnings VS Forward Price EarningsAQST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQST Per share dataAQST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.81%
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

AQST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (6/20/2025, 8:15:34 PM)

After market: 3.1801 -0.07 (-2.15%)

3.25

-0.15 (-4.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners43.76%
Inst Owner Change2.76%
Ins Owners5.6%
Ins Owner Change13.22%
Market Cap322.82M
Analysts84
Price Target8.59 (164.31%)
Short Float %12.61%
Short Ratio7.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-37.83%
Min EPS beat(2)-38.41%
Max EPS beat(2)-37.26%
EPS beat(4)1
Avg EPS beat(4)0%
Min EPS beat(4)-38.41%
Max EPS beat(4)76.28%
EPS beat(8)3
Avg EPS beat(8)-5.79%
EPS beat(12)7
Avg EPS beat(12)1.95%
EPS beat(16)11
Avg EPS beat(16)7.02%
Revenue beat(2)0
Avg Revenue beat(2)-24.73%
Min Revenue beat(2)-30.1%
Max Revenue beat(2)-19.36%
Revenue beat(4)2
Avg Revenue beat(4)3.6%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)59.16%
Revenue beat(8)3
Avg Revenue beat(8)2.31%
Revenue beat(12)7
Avg Revenue beat(12)4.47%
Revenue beat(16)11
Avg Revenue beat(16)10.36%
PT rev (1m)-14.65%
PT rev (3m)-22.31%
EPS NQ rev (1m)-7.61%
EPS NQ rev (3m)-3.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.93%
Revenue NQ rev (1m)-1.37%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)-1.97%
Revenue NY rev (3m)-14.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.95
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.55
BVpS-0.61
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.4%
FCFM N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score3
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.77%
Cap/Sales 0.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.87
Quick Ratio 4.48
Altman-Z -4.01
F-Score3
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.18%
EPS Next Y-36.33%
EPS Next 2Y-10.81%
EPS Next 3Y11.48%
EPS Next 5Y19.83%
Revenue 1Y (TTM)5.3%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-27.65%
Revenue Next Year-23.28%
Revenue Next 2Y4.41%
Revenue Next 3Y18.57%
Revenue Next 5Y31.32%
EBIT growth 1Y-111.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-82.76%
EBIT Next 3Y39.87%
EBIT Next 5Y37.99%
FCF growth 1Y-542.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-461.03%
OCF growth 3YN/A
OCF growth 5YN/A